Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07735728) titled 'A First-in-Human Study of ZE66-0205 in Healthy Volunteers' on July 24.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Other. Masking: Single (Participant).

Primary Sponsor: Eilean Therapeutics

Condition: Healthy Volunteers (HV)

Intervention: Drug: ZE66-0205

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: August 15, 2026

Target Sample Size: 32

Countries of Recruitment: Australia

To know more, visit https://clinicaltrials.gov/study/NCT07735728

Disclaimer: Curated by HT Syndication....